Fighting Cancer: Allostery and Targeting Cancer Cell Metabolism

March 23, 2017
Session 3 of the 2017 Drug Design and Delivery Symposium


Molecules in a cross-hair with a #3

The development of cancer is driven by the acquisition of multiple alterations in normal human cells that allow dysregulated proliferation. Join Stefan Gross of Agios Pharmaceuticals and Scott Edmondson of AstraZeneca as they discuss how targeting these unique adaptations could lead to drugs with potential to transform clinical outcomes across many cancer types.

What You Will Learn

  • Rationale for Targeting Cancer Cell Metabolism
  • Drugging Glycolysis: Activators of Pyruvate Kinase
  • Targeting the TCA Cycle: Inhibitors of Isocitrate Dehydrogenase and Glutaminase

The Fine Print

ACS Webinars® does not endorse any products or services. The views expressed in this presentation are those of the presenters and do not necessarily reflect the views or policies of the American Chemical Society.

Access to this recording is an exclusive benefit for ACS Members. Find out more about the benefits of membership.

ACS Webinars logo

Experts

Stefan Gross
Agios Pharmaceuticals

Scott D. Edmondson
AstraZeneca 

Co-Produced By